Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Bilia in connection with the issuance and repurchase of bonds
Mandate

Vinge has advised Bilia in connection with the issuance and repurchase of bonds

October 09, 2018 Capital Markets and Public M&A

Vinge has advised Bilia AB (publ) in connection with the issue of new senior and non subordinated bonds with a framework amount of SEK 1 500 000 000 as well as the repurchase of SEK 500 000 000 of a previously issued senior and non subordinated bond with a maturity date in 2021.

Initially, a bond in the amount of SEK 800 000 000 was issued, of which SEK 500 000 000 will be used for the repurchase of the previously issued bond and the remaining amount for repayment of bank loans as well as part financing of Bilia’s acquisitions in Belgium. 

The newly issued bonds have a term of 5 years and are subject to a variable interest of STIBOR 3M + 1.40%. 

Vinge’s team primarily consisted of Anders Strid, Lina André and Henrik Wastenson (tax).
 

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024